• Oncoinvent flagged a Phase 2 randomized ovarian cancer trial of intraperitoneal radium-224 therapy as ongoing clinical development for Radspherin.
• The trial-in-progress abstract is scheduled for future presentation at ESMO 2026 in Madrid on Oct. 24.
• Separate Radspherin program work on manufacturing and dosimetry is due to be presented at EANM 2026 in Vienna on Oct. 19.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief via Cision (Ref. ID: 202609300100BITN____UKPR__EN_20260929-BIT-6927-0) on September 30, 2026, and is solely responsible for the information contained therein.